CREATION OF STRAIN PRODUCING SPECIES-SPECIFIC INTERFERON-ALPHA FOR DEVELOPMENT OF ANTIVIRAL PREPARATIONS FOR SHEEPS
Abstract
Infectious diseases became a serious problem for sheep breeding, leading to significant economic losses. The aim of this study: to examine the feasibility of using recombinant interferons as a basis for development of antiviral preparations for sheeps. With reference to comparative analysis of IFN amino acid sequences we can suppose, that neither of the existing IFNbased veterinary preparations is suitable for therapy of ovine viral diseases. Also during this work, synthesized sequence of ovine interferon-α1 gene was cloned in Escherichia coli cells.
About the Authors
K. V. Vostrykava
Belarusian State University
Belarus
Postgraduate student
Belarus
Postgraduate student
S. G. Golenchenko
Belarusian State University
Belarus
Researcher
Belarus
Researcher
M. I. Patapovich
Belarusian State University
Belarus
Head of Laboratory
Belarus
Head of Laboratory
U. A. Prakulevich
Belarusian State University
Belarus
D. Sc. (Biol.), Professor, Head of Department
Belarus
D. Sc. (Biol.), Professor, Head of Department
References
1. Ostrikova, K. V., Potapovich, M. I. and Prakulevich, V. A. (2014), “Cloning and expression of genes sheep α2- and γ-interferon in the cells of E. coli.”, Biologiya – nauka XXI vek: sbornik tezisov 18-i Mezhdunarodnoi Pushchinskoi shkolykonferentsii molodykh uchenykh, Pushchino, 21–26 aprel᾿ 2014 g. [Biology – the science of the XXI century: Sat. mes. 18th Intern. Pushchino School Conf. young scientists, Pushchino, 21–26 April 2014], Biologiya – nauka XXI vek [Biology – the science of the XXI century], Pushchino, RU, 21–26 April 2014, pp. 72–73.
2. U. S. Department of Health and human Services (2016) FDA: U. S. Food and Drug Administration, Available at: http:// www.fda.gov (Accessed 24.05.2016).
3. European medicines agency (2016) Science medicines health, Available at: http://www.ema.europa.eu (Accessed 24.05.2016).
4. Kalliolias, G. and Ivashkiv, L. (2010), “Overview of the biology of type I interferons”, Arthritis Research & Therapy, vol. 12 (Suppl. 1), рр. 1–9.
5. Schultz, U., Kaspers, B. and Staeheli, P. (2004), “The interferon system of non-mammalian vertebrates”, Developmental and Comparative Immunology, vol. 28 (5), pp. 499–508.
6. Meager, A. (2006) The Interferons: Characterization and Application, in Meager, A. (ed.), WILEY-VCH Verlag.
7. Thomas, C., Moraga, I., Levin, D., Krutzik, P. O., Podoplelova, Y. Trejo, A., Lee, C., Yarden, G., Vleck, S. E., Glenn, J. S., Nolan, G. P., Piehler, J., Schreiber, G. and Garcia, K. C. (2011), “Structural linkage between ligand discrimination and receptor activation by type I interferons”, Cell, vol. 146, pp. 621–632.
8. Mogensen, K. E., Lewerenz, M., Reboul, J., Lutfalla, G. and Uzé, G. (1999), “The type I interferon receptor: structure, function, and evolution of a family”, Journal Interferon Cytokine Research, vol. 19, pp. 1069–1098.
9. Roberts, R. M. (1996), “Interferon-tau and pregnancy”, Journal Interferon Cytokine Research, vol. 16 (4), pp. 271–273.
10. Herzyk, D. J. (2003), “The immunogenicity of therapeutic cytokines”, Current Opinion in Molecular Therapeutics, vol. 5, pp. 167–171.
11. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A. and Struhl, K. (2003), Current protocols in molecular biology, John Wiley & Sons Inc.
12. Laemmli, U. K. (1970), “Cleavage of structural proteins during the assembly the head of bacteriophage T4”, Nature (Lond.), vol. 227, pp. 680–685.
13. Sen, C. (2001), “Viruses and Interferons”, Annual Review of Microbiology, vol. 55, pp. 255–282.
14. Fish, E. N. (1992), “Definition of Receptor Binding Domains in Interferon-α”, Journal of Interferon Research, vol. 12, pp. 257–266.
Review
Views: 675
Email this article 
